SAM #26-006772

NIH Sole Source Notice: Oxford Nanopore PromethION 2 Integrated Instrument

This notice announces NIH Clinical Center's intent to sole source a genomic sequencing instrument. - Agency: National Institutes of Health (NIH), Clinical Center, Department of Laboratory Medicine (DLM) - Sole source procurement to Oxford Nanopore Technologies Inc. - Product: PromethION 2 Integrated Instrument for long-read genomic DNA sequencing - Used to detect DNA mutations, structural abnormalities, and methylation in patient samples - Required for advanced sequencing not possible with standard techniques - Oxford Nanopore Technologies is the OEM and sole vendor capable of meeting requirements - Justification: Single source under FAR 13.106-1(b)(1) - No other vendors or OEMs mentioned - Interested parties may submit capability statements with proof of OEM authorization and relevant past performance - No specific part numbers or purchase quantities provided - Commercial opportunity for OEM-authorized vendors with relevant experience

Description

This is a Notice of Intent, not a request for quotation (RFQ). A solicitation document will not be issued, and quotations will not be requested.

The National Institutes of Health (NIH), Clinical Center, Department of Laboratory Medicine (DLM) intends to award a sole source firm-fixed-price contract to Oxford Nanopore Technologies Inc. for the procurement of PromethION 2 Integrated Instrument.

The purpose of this procurement is to secure Oxford Nanopore PromethION 2 Integrated instrument to be used to perform long read genomic DNA sequencing of patient samples to detect DNA mutations, DNA structural abnormalities (e.g., deletions, insertions, and inversions, etc.), and DNA methylation that are often undetected by commonly used DNA sequencing techniques in the hematology clinical research lab.

The Oxford Nanopore PromethION 2 Integrated instrument will be used to perform long read genomic DNA sequencing of patient samples to detect DNA mutations, DNA structural abnormalities (e.g., deletions, insertions, and inversions, etc.), and DNA methylation that are often undetected by commonly used DNA sequencing techniques. Oxford Nanopore is the original instrument and reagent manufacturer and is the only vendor with the capacity of performing these kinds of tests. After research validation of the tests, the reagents could be used to validate the patient testing system according to regulatory and accreditation requirements. It is therefore deemed to be in the Government’s best interest that this instrument is procured from Oxford Nanopore.

The Department of Laboratory Medicine serves as the clinical laboratory of the NIH Clinical Center. It provides laboratory support for patient care and research protocols and performs research and training in disciplines of Clinical Hematological Pathology.  In doing so it provides state-of-the-art laboratory testing in support of Clinical Center patient care and serves as a center of excellence in research and training in laboratory medicine, particularly in areas which utilize the unique strengths of the National Institutes of Health.

Background

The Department of Laboratory Medicine serves as the clinical laboratory of the NIH Clinical Center. It provides laboratory support for patient care and research protocols and performs research and training in disciplines of Clinical Hematological Pathology.

Rationale:

Oxford Nanopore is the original instrument manufacturer and sole vendor for instruments of these kinds of tests, i.e., long read sequencing to detect DNA mutations, DNA structural abnormalities (e.g., deletions, insertions, and inversions, etc.), and DNA methylation from patient samples. It is advisable to use Oxford Nanopore long-read sequencing for testing of samples from patients with cancer, cancer predisposing disorders, and with complicated clinical and pathological phenotypes.

Authority

This acquisition is being conducted in accordance with:

FAR 13.106-1(b)(1) – Soliciting from a Single Source

Under this authority, the Contracting Officer may solicit from a single source when it is determined that only one source is reasonably available to meet the Government’s requirements.

Acquisitions conducted under FAR Part 13 – Simplified Acquisition

Procedures are exempt from the competition requirements of FAR Part 6.

Responses

This is not a request for quotations. However, interested parties may submit a capability statement demonstrating their ability to meet the Government’s requirement.

Responses must include:

Company name and address

Technical capability

Proof of OEM authorization

Relevant past performance

The Government will evaluate capability statements received in response to this notice. The determination not to compete this requirement is solely within the discretion of the Government.

Submission Instructions

Responses referencing POTS: 26-006772 must be submitted electronically no later than July 7, 2026, at 12:00 PM EST to:

Gregory Noland

Contract Specialist

Hospital and Laboratory Support Division

Office of Acquisitions and Logistics Management

National Institutes of Health

Email: gregory.noland@nih.gov

View original listing